FDA approves 40 mg/mL Copaxone for�3 times a week

March 15, 2014 Peiqing Qian, M.D.

The U.S. Food and Drug Administration (FDA) has approved the three-times-a-week COPAXONE® 40mg/mL, a new dose of COPAXONE® on Jan 28, 2014.  This new formulation will allow for a less frequent dosing regimen administered by injection for patients with relapsing forms of multiple sclerosis (MS). In addition to the newly approved dose, daily COPAXONE® 20 mg/mL will continue to be available.

The FDA approval is based on data from the Phase III Glatiramer Acetate Low-Frequency Administration (GALA) study of more than 1400 patients, which showed that a 40 mg/mL dose of COPAXONE® administered by injection three-times-a-week significantly reduced relapse rates at 12 months compared to placebo.   It also demonstrated a favorable safety and tolerability profile in patients with relapsing MS.  

The availability of three-times-a-week COPAXONE® 40 mg/mL is an advancement for patients as they now have the option of effective and safe treatment with COPAXONE®, while reducing the number of injections by 60 percent.  Direct comparison of efficacy between the Copaxone 40 mg/ml three-times-a-week and 20 mg/mL daily injection treatment is not available.  For patient who is currently on Copaxone 20mg/ml daily injection treatment or is considering the 40 mg/ml three-times-a-week Copaxone as their new DMT, they should discuss these two available Copaxone dosing options with their MS care provider to see if Copaxone 40 mg/ml three-times-a-week is a good choice for them.  

Previous Article
FDA declines approval of Lemtrada for the treatment of MS

On December 30, 2013, the US Food and Drug Administration declined to approve the use of alemtuzumab (Lemtr...

Next Article
Weak link between epsilon toxin and MS

A recent article has been published suggesting that MS may be caused by a bacterial toxin. The bacteria i...